BIO-Europe Spring® 2017: Newron CEO on Xadago and upcoming pipeline milestones

April 11, 2017

Newron CEO Stefan Weber discusses the company's Parkinson's therapy, Xadago (safinamide), on the eve of its US market approval during the recent BIO-Europe Spring partnering conference. Newron, a clinical-stage biopharma company listed on the Swiss Exchange, is focused on the development of novel therapies for patients with diseases of the central nervous system. As well as Xadago—developed in partnership with Zambon, which holds global marketing rights to the product with the exception of Asia—Newron has three other clinical assets in its pipeline. Its most advanced is sarizotan, a serotonin 1A (5-HT1A) receptor agonist in development for the treatment of orphan disease Rett syndrome.

 

Click here for more coverage of the activities held during BIO-Europe Spring

Previous Article
Using Partnerships, Hua Medicine Brings Novel Diabetes Drug to Phase III
Using Partnerships, Hua Medicine Brings Novel Diabetes Drug to Phase III

Li Chen, PhD, co-founded Hua Medicine (Shanghai) six years ago with Ge Li, PhD, founder of WuXi AppTec. The...

Next Video
BIO-Europe Spring® 2017: Biomunex CEO on earlier deals for cancer drugs
BIO-Europe Spring® 2017: Biomunex CEO on earlier deals for cancer drugs

During the recent BIO-Europe Spring partnering conference in Barcelona, Biomunex CEO Pierre-Emmanuel Gerard...